Literature DB >> 34950931

Postprocedural development of left upper extremity mass.

Kayla Baker1, Lindsay Tjiattas-Saleski2.   

Abstract

Entities:  

Year:  2021        PMID: 34950931      PMCID: PMC8673563          DOI: 10.1002/emp2.12624

Source DB:  PubMed          Journal:  J Am Coll Emerg Physicians Open        ISSN: 2688-1152


× No keyword cloud information.

PATIENT PRESENTATION

An 89‐year‐old male presented to the emergency department for a lump near his antecubital fossa of his left upper extremity. He recently underwent percutaneous left brachial artery access for splenic artery embolization. Post procedure, he developed swelling around the intravenous site and numbness in the fingers of his left hand with decreased grip strength. On physical examination, there was a mass over the left medial epicondylar region with no erythema, edema, tenderness, or warmth (Figure 1). The lesion was not pulsatile. He had associated decrease pincher grasp of his left upper extremity. An ultrasound of the mass was ordered.
FIGURE 1

Mass over the left medial epicondylar region

Mass over the left medial epicondylar region

DIAGNOSIS

Pseudoaneurysm

Ultrasound of the left upper extremity showed an anechoic structure measuring 7.0 × 2.6 cm (Figure 2). Doppler of the structure revealed a swirling color flow and a small neck feeding the vessel near the medial left distal humerus soft tissue. This bidirectional blood flow creates a “Yin‐Yang” appearance, which is a classic ultrasound finding for pseudoaneurysms (Figure 3). Pseudoaneurysms most commonly occur as complications of endovascular procedures 0.5% to 2% of the time. They are a known complication of endovascular procedures with the femoral artery, which is the most common arterial access. However, the arteries in the upper extremity are becoming more favored for procedural use because of fewer hospital complications as compared to femoral access. Recognition of a pseudoaneurysm is imperative because of the risk of rupture, hemorrhage, and potential distal ischemia due to reduced blood flow. , Some pseudoaneurysms with diameters of less than 1.8 cm may spontaneously resolve. , For those larger in diameter, thrombin injection is the preferred treatment. , Ultrasound guided direct compression may also be used to resolve pseudoaneurysms non‐invasively. Surgical repair is reserved for those patients who fail either the thrombin injection or direct compression. This patient was ultimately referred to vascular surgery for repair.
FIGURE 2

Anechoic structure along the left distal humerus measuring 7.0 × 2.6 cm

FIGURE 3

Internal swirling on ultrasound color Doppler flow demonstrating the classic “Yin‐Yang” sign of a pseudoaneurysm

Anechoic structure along the left distal humerus measuring 7.0 × 2.6 cm Internal swirling on ultrasound color Doppler flow demonstrating the classic “Yin‐Yang” sign of a pseudoaneurysm
  4 in total

Review 1.  Contemporary management of postcatheterization pseudoaneurysms.

Authors:  Geoffrey W Webber; James Jang; Susan Gustavson; Jeffrey W Olin
Journal:  Circulation       Date:  2007-05-22       Impact factor: 29.690

2.  Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: a large single-center experience.

Authors:  Jonas Eichhöfer; Eric Horlick; Joan Ivanov; Peter H Seidelin; John R Ross; Douglas Ing; Paul Daly; Karen Mackie; Brenda Ridley; Leonard Schwartz; Alan Barolet; Vladimír Dzavík
Journal:  Am Heart J       Date:  2008-11       Impact factor: 4.749

3.  Radial Artery Pseudoaneurysm.

Authors:  Rick Tosti; Sezai Özkan; Robert M Schainfeld; Kyle R Eberlin
Journal:  J Hand Surg Am       Date:  2017-03-01       Impact factor: 2.230

4.  Postcatheterization femoral artery pseudoaneurysms: therapeutic options. A case-controlled study.

Authors:  Hussein A Heis; Kamal E Bani-Hani; Mwaffaq A Elheis; Rami J Yaghan; Bayan K Bani-Hani
Journal:  Int J Surg       Date:  2008-03-19       Impact factor: 6.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.